Division of Hematology/Oncology and Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Semin Hematol. 2010 Jan;47(1):3-12. doi: 10.1053/j.seminhematol.2009.10.011.
In October 1988, the world's first umbilical cord blood transplant (UCBT) was performed. Despite considerable skepticism initially by both scientists and clinical specialists in the field, umbilical cord blood (UCB) has now become one of the most commonly used sources of hematopoietic stem cells (HSCs) for allogeneic transplantation. Today, an estimated 600,000 UCB units have been banked and 20,000 UCB units have been distributed worldwide for both adults and children with life-threatening malignant and nonmalignant diseases. During this first generation of UCBT, substantial advances have been made resulting in better outcomes for our patients. UCB serves as an extraordinary example of translational medicine at its best, where clinical problems compel scientists to move basic discoveries into novel therapeutic approaches. This chapter briefly summarizes the highpoints of the history of UCBT with speculations as to what the next generation of research promises to discover.
1988 年 10 月，全球首例脐带血移植（UCBT）完成。尽管最初科学家和该领域的临床专家对此持相当大的怀疑态度，但脐带血（UCB）现在已成为同种异体移植中最常用的造血干细胞（HSCs）来源之一。如今，据估计已经有 60 万份 UCB 被储存，全球范围内已经分发了 2 万份 UCB 用于治疗患有危及生命的恶性和非恶性疾病的成人和儿童。在第一代 UCBT 期间，取得了重大进展，为我们的患者带来了更好的结果。UCB 是转化医学的杰出范例，临床问题促使科学家将基础发现转化为新的治疗方法。本章简要总结了 UCBT 的历史要点，并推测下一代研究有望发现什么。
